skip to main content
Idioma:
Resultados 1 2 3 4 5 next page
Refinado por: Nome da Publicação: Journal of Clinical Oncology remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance
Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance
Material Type:
Artigo 		Adicionar ao Meu Espaço

Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance

Scott Kopetz Paulo M Hoff; Jeffrey S Morris; Robert A Wolff; Cathy Eng; Katrina Y Glover; Rosie Adinin; Michael J Overman; Vincete Valero; Sijin Wen; Christopher Lieu; Shaoyu Yan; Hai T Tran; Lee M Ellis; James L Abbruzzese; John V Heymach

Journal of Clinical Oncology New York v. 28, n. 3, p. 453-459, 2010

New York 2010

Acesso online. A biblioteca também possui exemplares impressos.

2
Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance
Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance
Material Type:
Artigo 		Adicionar ao Meu Espaço

Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance

Scott Kopetz Paulo M Hoff; Jeffrey S Morris; Robert A Wolff; Cathy Eng; Katrina Y Glover; Rosie Adinin; Michael J Overman; Vincete Valero; Sijin Wen; Christopher Lieu; Shaoyu Yan; Hai T Tran; Lee M Ellis; James L Abbruzzese; John V Heymach

Journal of Clinical Oncology New York v. 28, n. 3, p. 453-459, 2010

New York 2010

Acesso online. A biblioteca também possui exemplares impressos.

3
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance)
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance)
Material Type:
Artigo 		Adicionar ao Meu Espaço

Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance)

Ellis, Matthew J ; Suman, Vera J ; Hoog, Jeremy ; Goncalves, Rodrigo ; Sanati, Souzan ; Creighton, Chad J ; DeSchryver, Katherine ; Crouch, Erika ; Brink, Amy ; Watson, Mark ; Luo, Jingqin ; Tao, Yu ; Barnes, Michael ; Dowsett, Mitchell ; Budd, G Thomas ; Winer, Eric ; Silverman, Paula ; Esserman, Laura ; Carey, Lisa ; Ma, Cynthia X ; Unzeitig, Gary ; Pluard, Timothy ; Whitworth, Pat ; Babiera, Gildy ; Guenther, J Michael ; Dayao, Zoneddy ; Ota, David ; Leitch, Marilyn ; Olson, Jr, John A ; Allred, D Craig ; Hunt, Kelly

Journal of clinical oncology, 2017-04, Vol.35 (10), p.1061-1069 [Periódico revisado por pares]

United States: American Society of Clinical Oncology

Texto completo disponível

Citações Citado por
4
Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study
Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study

Ellis, Matthew J ; Llombart-Cussac, Antonio ; Feltl, David ; Dewar, John A ; Jasiówka, Marek ; Hewson, Nicola ; Rukazenkov, Yuri ; Robertson, John F R

Journal of clinical oncology, 2015-11, Vol.33 (32), p.3781-3787 [Periódico revisado por pares]

United States: American Society of Clinical Oncology

Texto completo disponível

Citações Citado por
5
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Material Type:
Artigo 		Adicionar ao Meu Espaço

Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes

PARKER, Joel S ; MULLINS, Michael ; QUACKENBUSH, John F ; STIJLEMAN, Inge J ; PALAZZO, Juan ; MARRON, J. S ; NOBEL, Andrew B ; MARDIS, Elaine ; NIELSEN, Torsten O ; ELLIS, Matthew J ; PEROU, Charles M ; BERNARD, Philip S ; CHEANG, Maggie C. U ; LEUNG, Samuel ; VODUC, David ; VICKERY, Tammi ; DAVIES, Sherri ; FAURON, Christiane ; XIAPING HE ; ZHIYUAN HU

Journal of clinical oncology, 2009-03, Vol.27 (8), p.1160-1167 [Periódico revisado por pares]

Alexandria, VA: American Society of Clinical Oncology

Texto completo disponível

Citações Citado por
6
Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor–Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype—ACOSOG Z1031
Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor–Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype—ACOSOG Z1031
Material Type:
Artigo 		Adicionar ao Meu Espaço

Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor–Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype—ACOSOG Z1031

ELLIS, Matthew J ; SUMAN, Vera J ; ESSERMAN, Laura J ; UNZEITIG, Gary W ; MARGENTHALER, Julie ; BABIERA, Gildy V ; KELLY MARCOM, P ; GUENTHER, Joseph M ; WATSON, Mark A ; LEITCH, Marilyn ; HUNT, Kelly ; OLSON, John A ; HOOG, Jeremy ; LI LIN ; SNIDER, Jacqueline ; PRAT, Aleix ; PARKER, Joel S ; JINGQIN LUO ; DESCHRYVER, Katherine ; CRAIG ALLRED, D

Journal of clinical oncology, 2011-06, Vol.29 (17), p.2342-2349 [Periódico revisado por pares]

Alexandria, VA: American Society of Clinical Oncology

Texto completo disponível

Citações Citado por
7
Activity of Fulvestrant 500 mg Versus Anastrozole 1 mg As First-Line Treatment for Advanced Breast Cancer: Results From the FIRST Study
Activity of Fulvestrant 500 mg Versus Anastrozole 1 mg As First-Line Treatment for Advanced Breast Cancer: Results From the FIRST Study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Activity of Fulvestrant 500 mg Versus Anastrozole 1 mg As First-Line Treatment for Advanced Breast Cancer: Results From the FIRST Study

ROBERTSON, John F. R ; LLOMBART-CUSSAC, Antonio ; ROLSKI, Janusz ; FELTL, David ; DEWAR, John ; MACPHERSON, Euan ; LINDEMANN, Justin ; ELLIS, Matthew J

Journal of clinical oncology, 2009-09, Vol.27 (27), p.4530-4535 [Periódico revisado por pares]

Alexandria, VA: American Society of Clinical Oncology

Texto completo disponível

Citações Citado por
8
Exemestane Versus Anastrozole in Postmenopausal Women With Early Breast Cancer: NCIC CTG MA.27—A Randomized Controlled Phase III Trial
Exemestane Versus Anastrozole in Postmenopausal Women With Early Breast Cancer: NCIC CTG MA.27—A Randomized Controlled Phase III Trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Exemestane Versus Anastrozole in Postmenopausal Women With Early Breast Cancer: NCIC CTG MA.27—A Randomized Controlled Phase III Trial

GOSS, Paul E ; INGLE, James N ; D'SOUZA, David P ; CHALCHAL, Haji ; SPADAFORA, Silvana ; STEARNS, Vered ; PEREZ, Edith A ; LIEDKE, Pedro E. R ; LANG, Istvan ; ELLIOTT, Catherine ; GELMON, Karen A ; CHAPMAN, Judy-Anne W ; PRITCHARD, Kathleen I ; SHEPHERD, Lois E ; ELLIS, Matthew J ; SLEDGE, George W ; BUDD, G. Thomas ; RABAGLIO, Manuela ; ANSARI, Rafat H ; JOHNSON, David B ; TOZER, Richard

Journal of clinical oncology, 2013-04, Vol.31 (11), p.1398-1404 [Periódico revisado por pares]

Alexandria, VA: American Society of Clinical Oncology

Texto completo disponível

Citações Citado por
9
Genome-Wide Associations and Functional Genomic Studies of Musculoskeletal Adverse Events in Women Receiving Aromatase Inhibitors
Genome-Wide Associations and Functional Genomic Studies of Musculoskeletal Adverse Events in Women Receiving Aromatase Inhibitors
Material Type:
Artigo 		Adicionar ao Meu Espaço

Genome-Wide Associations and Functional Genomic Studies of Musculoskeletal Adverse Events in Women Receiving Aromatase Inhibitors

Ingle, James N ; Schaid, Daniel J ; Goss, Paul E ; Liu, Mohan ; Mushiroda, Taisei ; Chapman, Judy-Anne W ; Kubo, Michiaki ; Jenkins, Gregory D ; Batzler, Anthony ; Shepherd, Lois ; Pater, Joseph ; Wang, Liewei ; Ellis, Matthew J ; Stearns, Vered ; Rohrer, Daniel C ; Goetz, Matthew P ; Pritchard, Kathleen I ; Flockhart, David A ; Nakamura, Yusuke ; Weinshilboum, Richard M

Journal of clinical oncology, 2010-11, Vol.28 (31), p.4674-4682 [Periódico revisado por pares]

Alexandria, VA: American Society of Clinical Oncology

Texto completo disponível

Citações Citado por
10
Relationship Between Plasma Estradiol Levels and Estrogen-Responsive Gene Expression in Estrogen Receptor–Positive Breast Cancer in Postmenopausal Women
Relationship Between Plasma Estradiol Levels and Estrogen-Responsive Gene Expression in Estrogen Receptor–Positive Breast Cancer in Postmenopausal Women
Material Type:
Artigo 		Adicionar ao Meu Espaço

Relationship Between Plasma Estradiol Levels and Estrogen-Responsive Gene Expression in Estrogen Receptor–Positive Breast Cancer in Postmenopausal Women

DUNBIER, Anita K ; ANDERSON, Helen ; PARKER, Joel S ; PEROU, Charles M ; ELLIS, Matthew J ; DOWSETT, Mitch ; GHAZOUI, Zara ; FOLKERD, Elizabeth J ; A'HERN, Roger ; CROWDER, Robert J ; HOOG, Jeremy ; SMITH, Ian E ; OSIN, Peter ; NERURKAR, Ashutosh

Journal of clinical oncology, 2010-03, Vol.28 (7), p.1161-1167 [Periódico revisado por pares]

Alexandria, VA: American Society of Clinical Oncology

Texto completo disponível

Citações Citado por
Resultados 1 2 3 4 5 next page

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Autor/Criador 

  1. Abbruzzese, J  (2)
  2. Ellis, L  (2)
  3. Yan, S  (2)
  4. Adinin, R  (2)
  5. Wen, S  (2)
  6. Overman, M  (2)
  7. Kopetz, S  (2)
  8. Hoff, P  (2)
  9. Valero, V  (2)
  10. Tran, H  (2)
  11. Eng, C  (2)
  12. Lieu, C  (2)
  13. Heymach, J  (2)
  14. Wolff, R  (2)
  15. Glover, K  (2)
  16. Morris, J  (2)
  17. Mais opções open sub menu

Data de Publicação 

De até
Refinar
  1. Antes de2010  (28)
  2. 2010Até2012  (55)
  3. 2013Até2015  (26)
  4. 2016Até2019  (30)
  5. Após 2019  (22)
  6. Mais opções open sub menu

Novas Pesquisas Sugeridas

Ignorar minha busca e procurar por tudo

Deste Autor:

  1. Abbruzzese, J
  2. Ellis, L
  3. Yan, S
  4. Adinin, R
  5. Wen, S

Neste Assunto:

  1. Oncology
  2. Life Sciences & Biomedicine
  3. Science & Technology
  4. Humans
  5. Female

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.